VBI Vaccines Inc. (NASDAQ:VBIV) raised $23.6 million in concurrent equity and debt financing

VBI Vaccines Inc. (NASDAQ:VBIV) announced that it has raised $23.6 million in concurrent equity and debt financing transactions with Perceptive Advisors. Under the terms of the equity financing, VBI sold an aggregate of 3,475,000 of its common shares at a price of $3.05 per share in a private placement to Perceptive Advisors, for total gross proceeds of approximately $10.6 million.

On last trading day, VBI Vaccines Inc. (NASDAQ:VBIV) traded 374738 shares and was closed at $3.55 per share. Company stock is -19.32% away from its one year high and is moving 29.09% ahead of its one year low. Stock monthly performance is recorded as 4.41% while its performance in last one week is 14.52%. VBIV quarterly performance is -10.13% while firm’s price to sale ratio is 322.07 and price to book ratio is 1.62.
Analyst’s Analysis on VBI Vaccines Inc. (NASDAQ:VBIV)
Number of analysts are eying on this stock and after detailed observation, they have given the stock mean target price of $8.00 while their mean recommendation is 2.00 (1=Buy, 5=sell). The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 1.67 on scale of 1-5.

Enduro Royalty Trust (NYSE:NDRO) announced a cash dividend payment of $0.028 per share is scheduled to be paid on December 14, 2016. Shareholders who purchased NDRO prior to the ex-dividend date are eligible for the cash dividend payment. At the current stock price of $3.75, the dividend yield is 8.98%.

Enduro Royalty Trust (NYSE:NDRO) shares moved to $4.15 after starting the day at $3.90 on Friday. The weekly volatility of NDRO is 4.43% and monthly volatility is 4.58%. Its weekly performance is 5.06% while year to date (YTD) performance is 83.60%.

What Analysts Say About Enduro Royalty Trust (NYSE:NDRO)
Stock has got outperform rating from no analyst of Thomson Reuters whereas 1 analyst given hold rating to the stock. Analyst’s mean target price for the firm is $2.00 while analysts mean recommendation is 4.00.

On last trading day, Mobile TeleSystems PJSC (NYSE:MBT) traded 2.29 Million shares and was closed at $9.02 per share. Company stock is -0.77% away from its one year high and is moving 93.94% ahead of its one year low. Stock monthly performance is recorded as 15.79% while its performance in last one week is 5.50%. MBT quarterly performance is 15.15% while firm’s price to sale ratio is 1.14 and price to book ratio is 4.40.
Analyst’s Analysis on Mobile TeleSystems PJSC (NYSE:MBT)
Number of analysts are eying on this stock, and after detailed observation, they have given the stock mean target price of $9.13 while their mean recommendation is 2.30 (1=Buy, 5=sell). The consensus recommendation by Thomson Reuters Analysts is Outperform for MBT and their mean rating for the stock is 2.12 on scale of 1-5.

Akorn, Inc. (NASDAQ:AKRX) shares moved to $18.60 after starting the day at $18.58 on Friday. The weekly volatility of AKRX is 4.48% and monthly volatility is 4.70%. Firm weekly performance is -6.44% while year to date (YTD) performance is -50.15%. Company net profit margin stands at 16.60% whereas its Gross Margin is 61.00%. This year company’s Earnings per Share (EPS) growth is 832.80% and next year’s estimated EPS growth is 0.54%.
What Analysts Say About Akorn, Inc. (NASDAQ:AKRX)
Stock has got outperform rating from 5 analysts of Thomson Reuters whereas 5 analysts given hold rating to the stock. Analyst’s mean target price for AKRX is $29.54 while analysts mean recommendation is 2.40.

1 comment

  1. John

    Having launched Sci-B-Vac commercially in 15 countries and having other vaccine candidates in the pipeline, VBI vaccine is considered as the under the radar company by the analysts. The vaccine candidates that are in the pipeline include- CMV, GBM, MB, Zika, and RSV.
    InMed has two products in the pipeline which are- INM-7 and INM-085. INM-7 is for the treatment of Epidermolysis Bullosa, and INM-085 is for the treatment of Glaucoma. Both of these products are expected to have billion dollars global market if they ever get commercialized.

Leave a Reply

Your email address will not be published. Required fields are marked *